Key references: Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised adults without HIV infection

  • Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014;44(12b):1350–63. https://www.ncbi.nlm.nih.gov/pubmed/25482745
  • Di Cocco P, Orlando G, Bonanni L, D'Angelo M, Clemente K, Greco S, et al. A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc 2009;41(4):1201–3. https://www.ncbi.nlm.nih.gov/pubmed/19460516
  • eviQ. Prophylaxis - Pneumocystis jiroveci (carinii) in cancer patients [v.5]. Sydney: Cancer Institute NSW; Last reviewed: 22 Sept 2017. https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/220-prophylaxis-pneumocystis-jiroveci-carinii
  • Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82(9):1052–9. https://www.ncbi.nlm.nih.gov/pubmed/17803871
  • Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis 2002;4(2):66–74. https://www.ncbi.nlm.nih.gov/pubmed/12220242
  • Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 2013;13(4):272–9 .https://www.ncbi.nlm.nih.gov/pubmed/23465020
  • Mitsides N, Green D, Middleton R, New D, Lamerton E, Allen J, et al. Dapsone-induced methemoglobinemia in renal transplant recipients: more prevalent than previously thought. Transpl Infect Dis 2014;16(1):37–43. https://www.ncbi.nlm.nih.gov/pubmed/24215452
  • Mitsides N, Greenan K, Green D, Middleton R, Lamerton E, Allen J, et al. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients. Nephrology (Carlton) 2014;19(3):157–63. https://www.ncbi.nlm.nih.gov/pubmed/24387294
  • Schwartz BS, Mawhorter SD. Parasitic infections in solid organ transplantation. Am J Transplant 2013;13(4):280–303 .https://www.ncbi.nlm.nih.gov/pubmed/23465021
  • Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999;29(6):1467–71. https://www.ncbi.nlm.nih.gov/pubmed/10585797
  • Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014;(10):CD005590. https://www.ncbi.nlm.nih.gov/pubmed/25269391
  • Urbancic KF, Ierino F, Phillips E, Mount PF, Mahony A, Trubiano JA. Taking the challenge: A protocolized approach to optimize Pneumocystis pneumonia prophylaxis in renal transplant recipients. Am J Transplant 2018;18(2):462–6. https://www.ncbi.nlm.nih.gov/pubmed/28898546
  • Urbancic KF, Pisasale D, Wight J, Trubiano JA. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. Transpl Infect Dis 2018:e12968. https://www.ncbi.nlm.nih.gov/pubmed/30030892